Leerink Partnrs Has Bearish Estimate for IRWD Q1 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will earn ($0.06) per share for the quarter, down from their previous forecast of $0.03. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.08 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. During the same quarter last year, the company earned $0.12 EPS.

Several other brokerages also recently issued reports on IRWD. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Craig Hallum dropped their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Finally, JMP Securities dropped their price objective on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Ironwood Pharmaceuticals Stock Up 3.8 %

Shares of NASDAQ IRWD opened at $2.18 on Monday. The firm’s 50-day simple moving average is $3.83 and its 200 day simple moving average is $4.39. The company has a market cap of $348.87 million, a price-to-earnings ratio of -72.67 and a beta of 0.29. Ironwood Pharmaceuticals has a 12-month low of $2.05 and a 12-month high of $15.70.

Insider Activity

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 12.90% of the stock is currently owned by company insiders.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV increased its stake in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the last quarter. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $45,000. SG Americas Securities LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $53,000. CIBC Asset Management Inc acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter valued at approximately $53,000. Finally, Diversified Trust Co acquired a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at approximately $52,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.